European journal of breast health最新文献

{"title":"Lupus Mastitis in a Young Female Mimicking a Breast Carcinoma; a Rare Entity Through a Case Report and Review of the Literature.","authors":"Ayşenur Oktay,&nbsp;Habib Ahmad Esmat,&nbsp;Özge Aslan,&nbsp;Ismayil Mirzafarli","doi":"10.4274/ejbh.galenos.2021.6361","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2021.6361","url":null,"abstract":"<p><p>Lupus mastitis (LM) is a rare presentation of lupus panniculitis (LP) that usually affects women of childbearing age and may mimic malignancy. The condition is recurrent and progresses along with the underlying disease. Breast pathology that may be associated with LM includes fat necrosis, calcification, fibrosis, scarring, and breast atrophy. Therefore, LM should be considered in the differential diagnosis of a suspicious breast mass on mammography or ultrasound, particularly if the patient has a background of systemic lupus erythematosus (SLE) or discoid lupus erythematosus (DLE). Traumatic procedures such as surgery or biopsy may worsen the condition and it is advisable to avoid biopsy if the diagnosis can be established through accurate patient history, with identification of typical clinical and radiological features. Thus, awareness of the radiologic and clinical features of LM is essential to avoid unnecessary interventional procedures that carry the potential for disease exacerbation. The authors present here the imaging findings of LM in a 37-year old female with SLE, which presented as bilateral palpable breast lumps.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734524/pdf/ejbh-18-13.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39721342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A New Modality for Breast Cancer Diagnosis During the COVID-19 Pandemic: A Case Report.","authors":"Florence Vibert,&nbsp;Camille Martel,&nbsp;Raluca Andreea Ionescu,&nbsp;Carole Mathelin,&nbsp;Shanti Ame","doi":"10.4274/ejbh.galenos.2021.2021-4-1","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2021.2021-4-1","url":null,"abstract":"<p><p>Organized screening for breast cancer (BC) was suspended in most countries of the world during the coronavirus disease-2019 (COVID-19) pandemic. Com-puted tomography (CT) scans of the chest, frequently performed in patients with severe forms of COVID-19, may detect asymptomatic breast abnormalities. A 72-year-old patient, with a severe form of COVID-19 underwent a diagnostic CT scan. This led to the unexpected discovery, at an early stage, of a 12 mm, high grade, Human epidermal growth factor receptor 2 positive BC, with a high proliferation index. After responding to chemotherapy, she was managed with conser-vative breast surgery with sentinel lymph node biopsy. Delayed management of BC can be responsible for poor outcomes. Patients with severe forms of COVID-19 are also at risk for developing BC due to common risk factors. Thirty percent of incidental breast lesions discovered on CT scans are undiagnosed BC. Careful study of the mammary glands on CT scan of patients with COVID-19 may allow early diagnosis of a malignant tumor in a high-risk population for BC and deprived of routine screening mammography.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734516/pdf/ejbh-18-91.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39958486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cystic Neutrophilic Granulomatous Mastitis Regression with the Tumor Necrosis Factor-α Inhibitor, Adalimumab.","authors":"Le Wen Chiu,&nbsp;Karen Goodwin,&nbsp;Poonam Vohra,&nbsp;Erin Amerson","doi":"10.4274/ejbh.galenos.2021.2021-7-2","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2021.2021-7-2","url":null,"abstract":"<p><p>Idiopathic granulomatous mastitis (IGM) is a rare, benign, inflammatory breast disease that primarily affects parous women within a period of five years post-partum. Cystic neutrophilic granulomatous mastitis (CNGM) is clinically identical to IGM, but histopathology demonstrates distinct central lipid vacuoles rimmed by neutrophils with an outer cuff of epithelioid histiocytes/granulomas, with inconsistent presence of Coryneform bacteria within the vacuoles. There is no consensus on the treatment for either IGM or CNGM, which may be managed surgically with wide local excision or mastectomy or medically with antibiotics, steroids, and steroid-sparing immunosuppressive agents. We present a 30-year-old woman with plaque psoriasis and CNGM whose breast symptoms resolved after treatment with the tumor necrosis factor alpha (TNF-α) inhibitor adalimumab, which has not previously been described as a treatment option for CNGM.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734519/pdf/ejbh-18-94.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39958487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What Has Changed During the COVID-19 Pandemic? - The Effect on an Academic Breast Department in Portugal.","authors":"Diana Simão,&nbsp;Mariana Sardinha,&nbsp;Ana Filipa Reis,&nbsp;Ana Sofia Spencer,&nbsp;Ricardo Luz,&nbsp;Sónia Oliveira","doi":"10.4274/ejbh.galenos.2021.2021-11-1","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2021.2021-11-1","url":null,"abstract":"<p><strong>Introduction: </strong>One year ago, Portugal entered its first lockdown because of the coronavirus disease-2019 (COVID-19) pandemic. The impact of this on delays in cancer diagnosis and treatment is a major concern, which may negatively affect the outcomes of these patients.</p><p><strong>Materials and methods: </strong>This retrospective, single-center analysis compared the clinical and pathological characteristics of breast cancer (BC) patients referred to a medical oncology first appointment between March 2020 and 2021, with the same period in the previous year.</p><p><strong>Results: </strong>Strikingly, there was a 40% reduction in the number of BC patients during lockdown. However, there was a statistically significant increase in the proportion of metastatic BC patients admitted for the first time for systemic therapy (13.6% vs. 28.9%, p = 0.003). Additionally, a statistically significant increase in the number of patients with bilateral early BC at diagnosis after March 2020 was found (7.2% vs. 1.9%, p = 0.043).</p><p><strong>Conclusion: </strong>These findings support international recommendations for an accelerated restoration of BC screening, to reduce incidence of advanced breast cancer at diagnosis and mitigate the expected impact of the COVID-19 pandemic on patients with cancer. Further work is needed to examine in detail the impact of measures to manage the COVID-19 pandemic on breast cancer outcomes.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734514/pdf/ejbh-18-74.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39958484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic Counseling, Screening and Risk-Reducing Surgery in Patients with Primary Breast Cancer and Germline BRCA Mutations: Unmet Needs in Low- and Middle-Income Countries.","authors":"Hiba A Moukadem, Ahmad Al Masry, Rula W Atwani, Firas Kreidieh, Lana E Khalil, Rita Saroufim, Sarah Daouk, Iman Abou Dalle, Nagi S El Saghir","doi":"10.4274/ejbh.galenos.2021.2021-5-1","DOIUrl":"10.4274/ejbh.galenos.2021.2021-5-1","url":null,"abstract":"<p><strong>Objective: </strong>Worldwide genetic counseling practices are variable and often not reported in low- and middle-income countries (LMICs). We present the follow-up genetic counseling, breast screening, risk-reducing salpingo-oophorectomy (RRSO) and contralateral prophylactic mastectomy (CPM) in a cohort of study patients with either <i>BRCA</i> pathogenic mutations or <i>BRCA</i> variant of unknown significance (VUS).</p><p><strong>Materials and methods: </strong>Chart review and phone calls for the collection of information. Out of a cohort of 250 patients, 14 had deleterious mutations and 31 had a VUS, of whom 19 had primary early breast cancer. We collected information about genetic counseling, screening, CPM and RRSO.</p><p><strong>Results: </strong>Fourteen patients with deleterious mutations (7 <i>BRCA1</i> and 7 <i>BRCA2</i>) and 19 patients with VUS mutations (20 VUS, 4 <i>BRCA1</i>, 16 <i>BRCA2</i>; 1 patient had both) were surveyed. Of 14 patients with deleterious <i>BRCA</i> mutations, 57.14% (8/14 patients) received genetic counseling from their oncologist. Subsequently 85.71% (12/14) are undergoing mammography screening and 35.71% (5/14) breast screening magnetic resonance imaging (MRI). Furthermore, 50% of them underwent CPM and 57.14% underwent RRSO. Of 19 patients with VUS mutations, 10.5% received genetic counseling from their oncologist; 78.9% were undergoing regular screening mammogram and 31.5% were undergoing breast MRI; one patient underwent CPM and two patients RRSO.</p><p><strong>Conclusion: </strong>Within three years from knowing they have a mutation, 50% of patients with germline <i>BRCA</i> mutations had undergone CPM and 60% RRSO, the majority of them had screening mammography surveillance but only 50% had screening MRI. Follow-up of patients with VUS with mammography was 78% but MRI was only 31%. Lack of MRI surveillance reflects both limited resources and insufficient counseling. Genetic counseling was done by medical oncologists, which reflects a trend in LMIC. Our Data shows the importance of the need for professional genetic counselors and optimal surveillance in Lebanon and other LMICs.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734520/pdf/ejbh-18-16.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39721343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Axillary Reverse Lymphatic Mapping in the Treatment of Axillary Accessory Breast Cancer: A Case Report and Review of Management.","authors":"Orli Friedman-Eldar,&nbsp;Siarhei Melnikau,&nbsp;Youley Tjendra,&nbsp;Eli Avisar","doi":"10.4274/ejbh.galenos.2021.2021-7-3","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2021.2021-7-3","url":null,"abstract":"<p><p>Accessory breast tissue is a rare aberration of normal breast development, that presents most commonly in the axilla. Similar to normal breast tissue, it can undergo physiologic and pathologic changes, including malignant transformation. We report a rare case of accessory breast cancer, treated with surgical resection and axillary reverse mapping (ARM), and review current literature focusing on management. We report a 68-year-old female with a history of left breast cancer treated with lumpectomy and axillary dissection, who later developed in-breast recurrence treated with re-lumpectomy and sentinel node biopsy which mapped at the contralateral (right) axilla, but was negative. Two years later screening imaging revealed right axillary tail focal asymmetry with two spiculated masses. Core biopsy showed invasive ductal carcinoma (IDC), and histologic examination of the biopsy could not determine whether this represents a new primary breast cancer or axillary metastasis from the contralateral site. She underwent lumpectomy of the two masses and sentinel node biopsy. During surgery, the masses were identified in the axilla itself, rather than the axillary tail. Final pathology revealed IDC, pT1N0(sn), and extensive ductal carcinoma <i>in situ</i> (DCIS). Due to positive margins, she underwent re-lumpectomy with ARM. Final pathology revealed residual DCIS with negative new margins. The patient was referred for adjuvant radiotherapy. Accessory axillary breast tissue can be confused with axillary tail tissue. It is necessary for the surgeon to distinguish between them by meticulous physical examination and radiologic evaluation, as resection of axillary breast tissue may warrant reverse lymphatic mapping for lymphedema prevention.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734517/pdf/ejbh-18-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39721340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuroendocrine Tumors of the Breast: Single-Center Experience.","authors":"Bermal Hasbay,&nbsp;Hüseyin Özgür Aytaç,&nbsp;Filiz Aka Bolat","doi":"10.4274/ejbh.galenos.2021.6349","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2021.6349","url":null,"abstract":"<p><strong>Objective: </strong>Breast carcinomas with neuroendocrine (NE) differentiation are extremely rare. The aim was to discuss breast cancer cases with NE differentiation in the light of World Health Organization 2019 classification and literature information.</p><p><strong>Material and methods: </strong>The pathology records of 56 cases diagnosed as neuroendocrine tumor (NET) and/or breast cancers with NE differentiation presenting to a single center between January 2010 and June 2020 were evaluated. The patients were evaluated in terms of age, tumor size, location, histological grade, hormone profiles (ER, PR, HER2), guideline American Joint Committee on Cancer, lymph node status, stage, metastases, progression, survival, radiological features, surgery type and therapy modality.</p><p><strong>Results: </strong>The age of the patients ranged from 34 to 81 years. Average tumor size was 2.3 cm. Median (range) follow up time was 31.5 (1-73 month). Metastatic lymph nodes were found in 20 cases. In our series, NE differentiation mostly accompanied invasive carcinoma of no special type, less frequently solid papillary carcinoma, and mucinous carcinoma.Four patients had a history of neoadjuvant chemotherapy. Response to treatment was very poor in all four cases. Synaptophysin and chromogranin were positive in 38 cases. No correlation was found among tumor size, grade, age, lymph node status, and presence of distant metastasis in our series.</p><p><strong>Conclusion: </strong>Clinical features and morphology may not help to distinguish NET from other subtypes of breast cancer. Therefore, the morphologic findings of a nested or trabecular architecture, nuclear or cytoplasmic features of NE differentiation, mucin production, or solid papillary growth pattern should prompt a pathologist to order NE markers.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734525/pdf/ejbh-18-30.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39721345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic Value of Axillary Ultrasound, MRI, and ¹⁸F-FDG-PET/ CT in Determining Axillary Lymph Node Status in Breast Cancer Patients.","authors":"Ayşegül Aktaş,&nbsp;Meryem Günay Gürleyik,&nbsp;Sibel Aydın Aksu,&nbsp;Fugen Aker,&nbsp;Serkan Güngör","doi":"10.4274/ejbh.galenos.2021.2021-3-10","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2021.2021-3-10","url":null,"abstract":"<p><strong>Objective: </strong>Knowing axillary lymph node (ALN) status before surgery affects decisions about treatment modalities. Therefore, reliable, noninvasive diagnostic methods are important for determining ALN metastases. We aimed to accurately evaluate the patient's ALN status with noninvasive imaging modalities while making treatment decisions.</p><p><strong>Materials and methods: </strong>Patients who received the axillary ultrasound (AUS), magnetic resonance imaging (MRI), or 18F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG-PET/CT) imaging modalities and whose ALNs were confirmed histopathologically by fine needle aspiration cytology (FNAC), sentinel lymph node biopsy (SLNB), or ALN dissection (ALND) were included in the study.</p><p><strong>Results: </strong>The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of AUS for the detection of ALN metastases were 83%, 62%, 59.2%, 54.8%, and 79.1%, respectively. For MRI they were 86.1%, 75%, 68.5%, 51.6%, and 85.3%, respectively, and for ¹⁸F-FDG-PET/CT they were 78%, 53%, 56.2%, 51.4%, and 72.5%, respectively. ALNs were found to be metastatic in all patients who were reported positive in all three imaging modalities. ALN metastases were detected in 19 of 132 patients (false negativity, 14.3%) in whom AUS, MRI, and ¹⁸F-FDG-PET/ CT images were all reported as negative.</p><p><strong>Conclusion: </strong>In our study, we found that the diagnostic performance of MRI was slightly better than AUS and ¹⁸F-FDG-PET/CT. When we used imaging modalities together, our accuracy rate was better than when we used them alone. For accurate evaluation of axillary lymph nodes, imaging modalities should be complementary rather than competitive.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734531/pdf/ejbh-18-37.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39721346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Undefined Oncological Risk of Fat Grafting Procedures in the Breast.","authors":"Charoo Piplani,&nbsp;Duneska D Obando,&nbsp;Andrea Ramírez,&nbsp;Natalia Cátala,&nbsp;John P Garcia,&nbsp;Ricardo A Torres-Guzman","doi":"10.4274/ejbh.galenos.2021.2021-9-3","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2021.2021-9-3","url":null,"abstract":"soft atrophy, pigmentation, local tissue Chronic radiation-induced injury functional impairment at reversing these changes by use of radioprotective agents, tissue debridement, skin grafting, local and free vascularized flaps, recently, adipose tissue grafting (2). The concept of fat grafting in 1893 plastic its in the breast, extremities, orbit, head neck. the undefined risk of oncological recurrence resulting from fat grafting into the irradiated breast tissue (1). The relationship between fat grafts and breast cancer cells explored in the past. One of the most extensive patient series was published by Petit et al. (3) in consisting of a multicenter analysis of 513 patients undergoing fat grafting after breast cancer. With an average follow-up time of 19.2 months, the study revealed a local recurrence rate of 2.4% (1.5%/year) and an overall recurrence of 5.6% (3.6%/ year). A higher locoregional recurrence rate was observed in carcinoma in situ patients compared to those with invasive cancer. with cancer in situ) between 1988 - 2009, with a three-year minimum follow-up period. Five patients (3.6% of the overall population) were diagnosed with local recurrence post fat grafting compared to four patients (2.9% of the overall population) between surgery and the first fat grafting procedure. It was concluded that fat grafting after mastectomy did not increase local oncological recurrence. Basic science and clinical studies have provided contradictory data on these procedures’ safety profiles, making it difficult to make a definitive claim about their oncologic safety. The primary concerns are the lack of an ideal control group for comparison, retrospective analysis by most publications, and inadequate follow-up. The lack of standardization of fat harvesting, processing, and technique further adds to the challenge. As proposed by Kenny et al (1), better animal models and a larger working group with a longer follow-up period can provide these answers. Additionally, we strongly feel that high-quality research focusing on irradiated tissue’s oncological potential following fat grafting can provide a better clinical correlation. We propose that basic science models be based on samples from the same patient as opposed to laboratory-stored cell lines. This can be done for individual case reports for better homology. Guidelines with a longer definite follow-up period and a strong control group must be accomplished. A definite wait time from previous procedures (if any), based on individual risk factors, must be implemented for any clinical trial in the field. The need for prospectively controlled long-term clinical trials must be encouraged. These measures will help answer these questions sooner and enable healthcare providers to safely use the fat grafting technique.","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734523/pdf/ejbh-18-105.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39844605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction.","authors":"","doi":"10.4274/ejbh.galenos.2021.2021-5-6.e001","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2021.2021-5-6.e001","url":null,"abstract":"<p><p>[This corrects the article on p. 302-307 in vol. 17, PMID: 34651107.].</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8734521/pdf/ejbh-18-107.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39844606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}